A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Synergy Health Network’s $100 Mil Expansion Starts with Crowdfunding via Rialto Markets

Ambitious ‘telehealth’ care company Synergy Health Network wants to be generating revenues of $100 million in just four years.

The Florida-based firm, founded by tech-savvy entrepreneur Brian Weinstein in November 2021, already generates $4.2 million annually by connecting patients to a broad range of healthcare services manned by specialists, rather than relying on AI (artificial intelligence) as preferred by many of its competitors.

Now it is giving investors the chance to back its expansion plans after teaming up with Rialto Markets to utilise the award-winning broker-dealer’s crowdfunding platform and infrastructure for a $1 million Reg CF raise to launch Synergy’s four-year growth mission.

“We are delighted Synergy Healthcare Network has chosen to work with us and use our platform and infrastructure to attract the investment to launch its four-year expansion project and hopefully deliver a healthy return on investment.”

“A US Department of Health report shows a 63-fold increase in the utilization of telehealth services from 840,000 in 2019 to 52.7 million in 2021 and is increasing. The US telehealth market is expected to expand at a compound annual growth rate of 31.2% from 2022 to 2027.

“We hope investors will seize the opportunity we are offering through Rialto Markets’ platform.”

Crowdfunding is now a popular way for innovative private companies to raise investment. The phenomenon raised $113.52 billion globally last year, according to Pitchbook data, a year-on-year increase of 1,021%.

Rialto Markets also operates a pioneering secondary market alternative trading system (ATS) which empowers the buying and selling of shares in private companies.

The ATS operates in a similar way as the Nasdaq and NYSE are used for public company trading, allowing private companies to access vital funding and investors to have more flexibility with liquifying holdings.

This includes equity crowdfunded companies and other forms of private securities including NFTs, crypto currencies and other types of digital assets in a much more regulated environment.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Noze states the grant will fund a groundbreaking clinical study aimed at detecting TB in high-burden countries, using the company's DiagNoze® — a handheld breathalyzer designed for the real-time detection and screening of various medical conditions, including infectious diseases such as TB.
Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."

By using this website you agree to accept Medical Device News Magazine Privacy Policy